Biocon Biologics And Civica Team To Launch Private-Label Insulin Glargine In The U.S.

(n){if(!window.cnxel){window.cnxel={},window.cnxel.cmd=[];var t=n.createElement('iframe');t.src='javascript:false'; t.display='none',t.onload=function(){var ...
Drug Store News

Biocon Biologics, Civica collaborate to expand insulin Aspart access

Biocon Biologics and Civica announced a strategic collaboration agreement to expand access and affordability of Insulin Aspart in the United States. Under the terms of the agreement, Biocon Biologics ...
Yahoo Finance

Biocon Biologics and Civica Expand Partnership and Launch Private-Label Insulin Glargine to Broaden U.S. Diabetes Treatment Options

BRIDGEWATER, N.J. and BENGALURU, India, Oct. 16, 2025 /PRNewswire/ -- Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523, NSE: ...

In shot across Big Pharma's bow, California will sell its own insulin

SACRAMENTO, California — California will start selling low-cost insulin in January, becoming the first state in the nation to bypass Big Pharma with its own supply of the expensive diabetes drug and ...

Biocon Biologics eyes expansion in the US insulin market

Biocon Biologics recently announced that it would manufacture and supply insulin glargine pens to Civica under a multi-year ...
MedPage Today

Faster-Acting Insulin Aspart Safe for Pregnant Women With Diabetes

HAMBURG, Germany -- Faster-acting insulin aspart was safe for pregnant women with type 1 or 2 diabetes and resulted in fewer events of hypoglycemia, the randomized CopenFast trial found. The mean ...
Longview News-Journal

Biocon Biologics and Civica, Inc. Collaborate to Expand Insulin Aspart Access in the United States

BRIDGEWATER, N.J. and PETERSBURG, Va. and BENGALURU, India, March 6, 2025 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE ...